{"denoms":[{"counts":[{"groupId":"BG000","value":"38"}],"units":"Participants"}],"groups":[{"description":"Participants received panobinostat 20 mg orally OD, three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle.","id":"BG000","title":"Panobinostat"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.58","value":"60"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Pacific islander"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The analysis was performed Full Analysis Set (FAS) was defined according to the Intention to Treat (ITT) principle. This population included all participants enrolled into the study. Enrolled patients were those who had received at least one dose of study medication."}